key: cord-0799729-wemn4jti
authors: Grumach, Anete S.; Goudouris, Ekaterini; Junior, Sergio Dortas; Marcelino, Fernanda Casares; Oliva Alonso, Maria Luiza; de Oliveira Martins, Raquel; Arpon, Maria Angelica; Rodrigues Valle, Solange Oliveira
title: COVID-19 AFFECTING HEREDITARY ANGIOEDEMA PATIENTS WITH AND WITHOUT C1 INHIBITOR DEFICIENCY
date: 2020-11-30
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.11.042
sha: 6ba87a2f5dbb3fa1d2a6b42da5f92eebb702b735
doc_id: 799729
cord_uid: wemn4jti

nan

commercial, or not-for-profit sectors. 51 At the beginning of the SARS-CoV-2 pandemic, age over 60 years, hypertension and 52 diabetes mellitus have been identified as the major risk factors for severe cases of 53 COVID-19. The knowledge about COVID-19´s immunopathogenesis has been 54 increasing rapidly. The pathogenicity of COVID-19 is not restricted to the respiratory 55 system, and a relevant inflammatory response producing systemic involvement was 56 associated with the severity of the disease. Also, thromboembolic phenomena were 57 evidenced clinically and through laboratory tests (1).

Hereditary Angioedema (HAE) is a rare, potentially life-threatening disorder 59 characterized by cutaneous and submucosal swelling attacks. It is caused by a 60 deficiency of C1 inhibitor (C1INH); however, an additional type of HAE with normal 61 C1 inhibitor levels has been described. The contact system's primary role was 

J o u r n a l P r e -p r o o f

Thrombotic complications of COVID-19

Complement activation in the disease course of COVID-19 and its effects on 177 clinical outcomes

A case report of COVID-19 virus infection in a patient with 180 hereditary angioedema

Idiopathic nonhistaminergic acquired 184 angioedema in a patient with coronavirus disease 2019

Rationale for targeting complement in COVID-19

Complement Inhibition in Coronavirus Disease 191 (COVID)-19: A Neglected Therapeutic Option

The central 194 role of endothelium in hereditary angioedema due to C1 inhibitor deficiency

Outcomes Associated With Use of a 198

Kinin B2 Receptor Antagonist Among Patients With COVID-19. JAMA 199 Netw Open

Complement activation in patients with COVID-19: A novel therapeutic 202 target

Acknowledgement: We are grateful for the collaboration of Brazilian Association of 206 Patients with HAE (ABRANGHE)